Statistical Communications in Infectious Diseases
Editor-in-Chief: Evans, Scott
1 Issue per year
Mathematical Citation Quotient (MCQ) 2016: 0.06
Free Trial Access Available!
Register with De Gruyter Online and get access to this and other selected journals. Simply register with De Gruyter Online, log in and go to your personal user account "My De Gruyter". Please enter your access token FREE-ACCESS into the field provided. Once you have redeemed your token, you will be able to access the free content via the respective journal page.
Readers of Statistical Communications in Infectious Diseases have free access to its articles. To access the articles, simply click on "Get access to full text" on any article you wish to view.
You can enjoy access to a number of De Gruyter economics journals. To enjoy access, click here.Your benefits
- Answering some of the most urgent issues of today
- Multidisciplinary approach
- Innovative methodologies
- Theoretical and practical outlook on infectious diseases
- High educational value of published materials
Aims and Scope
The mission of Statistical Communications in Infectious Diseases is to serve as the primary vehicle for the communication and education of statistical thinking in infectious disease research and policy.
The infectious diseases community faces many difficult challenges. These include: (1) coping with continuing high-impact diseases such as HIV, malaria, TB, and flu; (2) dealing with infectious disease outbreaks such as Ebola, pandemic avian influenza, or SARS; and (3) preparing for the inevitable emergence of diseases that are unknown or are recognized but will reemerge in a more threatening form (e.g., antibiotic resistant [nightmare] bacteria or superbugs). Research in infectious diseases is also challenged by funding limitations, politics, and ethical dilemmas.
Increasingly complex data is also creating new challenges to the design and analysis of research studies. Enhanced statistical expertise is essential to address these challenges and to develop and evaluate medical and public health responses to potential outbreaks and epidemics.
Statistical Communications in Infectious Diseases (SCID) publishes significant research on the application of statistical ideas to problems arising from studies of infectious diseases. SCID takes a broad perspective on the role of statistics in infectious disease research including application, policy, education and theory. SCID fosters much-needed communication among statisticians on the best approaches to evolving complex infectious disease data, and is a venue for statisticians to enter a dialogue with other scientists and policy makers on the strengths and limitations of policies and methods for design, monitoring, analysis, and reporting of infectious disease research studies.
SCID goes beyond the application of statistical methods to data arising from infectious disease studies or new statistical strategies. SCID serves as a sounding board to discuss policy issues, as well as to accomplish the following goals: (1) engage and raise the quality of the discussions of important issues in the public and scientific press; (2) ensure that optimal scientific tools are utilized in infectious disease research; (3) improve the training and practice of the next generation of professionals involved in infectious diseases research through educational articles; (4) raise the profile of quantitative science in infectious disease research by demonstrating its value in decision making and public health.Topics
- How heavily should the public invest in research or implementation of different prevention modalities?
- What is necessary to achieve control of epidemics (for example, do we require a vaccine to control the spread of HIV or what procedures are required to halt the spread of Ebola)?
- How can statisticians help with grass roots epidemic control efforts?
- How can we optimally evaluate the benefits vs. harms vs. costs of competing interventions?
- How can we best characterize the trade-offs between civil liberties and public safety?
- How should we adjust the traditionally required level of evidence to address areas of unmet medical need?
- How do we revise our traditional approaches to the design, monitoring, analyses, and reporting of infectious disease studies to improve medical practice and public health?
Original research articles, book reviews
- Type of Publication:
Researchers, practitioners, educators, policy makers, students, and institutions interested in infectious diseases
Submission of Manuscripts
Instructions for Authors
Online Submission of Manuscripts
- Internationally recognized editorial board
- Fast access to articles
- Every article easily discoverable because of Search Engine Optimization (SEO) and comprehensive abstracting and indexing services
- Convenient citation tracking via e-mail alert
- Secure archiving by De Gruyter and the independent archiving service Portico
- Professional sales and marketing activities
- Please submit your manuscript via our Online Submission Tool following the Instructions for Authors
- Publication for all papers accepted after peer reviewing procedure
- In case of any problems editorial assistance will be provided
- Contributions submitted to this journal must be written in clear and concise English
- Before submitting a paper please get familiar with our Publication Ethics and Malpractice Statement as well as Copyright Agreement
- Once your article is accepted you have the option to publish it open access
- Our repository policy allows you to distribute 30 PDF copies of your published article to colleagues (the PDF has to include the information that it is an author's copy). Please also feel free to distribute the link to the online abstract
- If you have any general questions please visit our FAQ page for authors
We look forward to receiving your manuscript!
Abstracting & Indexing
Statistical Communications in Infectious Diseases is covered by the following services:
- Baidu Scholar
- CABI (over 50 subsections)
- CNKI Scholar (China National Knowledge Infrastructure)
- Current Index to Statistics
- EBSCO (relevant databases)
- EBSCO Discovery Service
- Genamics JournalSeek
- Google Scholar
- Japan Science and Technology Agency (JST)
- KESLI-NDSL (Korean National Discovery for Science Leaders)
- Mathematical Reviews (MathSciNet)
- Microsoft Academic
- Naviga (Softweco)
- Primo Central (ExLibris)
- ProQuest (relevant databases)
- Summon (Serials Solutions/ProQuest)
- Ulrich's Periodicals Directory/ulrichsweb
- WanFang Data
- WorldCat (OCLC)
- Zentralblatt Math (zbMATH)
Scott R. Evans, Department of Biostatistics and the Center for Biostatistics in AIDS Research, Harvard University, USA (email@example.com)
Alfred Balch, University of Utah (Alfred.Balch@hsc.utah.edu)
Brad J. Biggerstaff, Division of Vector-Borne Diseases, Centers for Disease Control and Prevention, USA (firstname.lastname@example.org)
Ron Bosch, Harvard T.H.Chan School of Public Health (email@example.com)
Ivan S.F. Chan, Abbvie Inc., USA (firstname.lastname@example.org)
Xiao Ding, Biostatistics, Gilead Sciences, Inc., USA (email@example.com)
Marion Ewell, The Emmes Corporation, USA (firstname.lastname@example.org)
Dean Follmann, National Institute of Allergy and Infectious Diseases, National Institutes of Health, USA (DFollmann@niaid.nih.gov)
Yonghong Gao, Biomedical Advanced Research and Development Authority, USA (Yonghong.Gao@hhs.gov)
Michael Hughes, Harvard T.H.Chan School of Public Health (email@example.com)
Lingling Li, Sanofi Genzyme, USA (Lingling_li@post.harvard.edu)
Honghu Liu, University of California Los Angeles (firstname.lastname@example.org)
Judith Lok, Harvard T.H.Chan School of Public Health (email@example.com)
Rhoderick Neri Machekano, Stellenbosch University, South Africa (firstname.lastname@example.org)
Olga Marchenko, Quintiles, USA (Olga.email@example.com)
Suzanne May, University of Washington, USA (firstname.lastname@example.org)
Farzad Noubary, Tufts University School of Medicine (FNoubary@tuftsmedicalcenter.org)
Dionne L. Price, Office of Biostatistics, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, USA (Dionne.Price@fda.hhs.gov)
Cavan Reilly, Division of Biostatistics, School of Public Health, University of Minnesota, USA (email@example.com)
Barbra Richardson, Department of Biostatistics, University of Washington, USA (firstname.lastname@example.org)
Dan Rubin, Office of Biostatistics, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, USA (Daniel.Rubin@fda.hhs.gov)
Pamela Shaw, Department of Biostatistics and Epidemiology, University of Pennsylvania, USA (email@example.com)
Norma Terrin, Tufts University School of Medicine (Nterrin@tuftsmedicalcenter.org)
Lu Tian, Department of Health Research and Policy, Stanford University, USA (firstname.lastname@example.org)
Kohei Uemura, Pharmaceutical and Medical Devices Agency, Japan (email@example.com)
Handan Wand, University of New South Wales, The Kirby Institute, Australia (Hwand@kirby.unsw.edu.au)
Rui Wang, Brigham and Women's Hospital and Harvard University, USA (firstname.lastname@example.org)
L.J. Wei, Harvard T.H.Chan School of Public Health (email@example.com)
Hulin Wu, University of Texas Health Science Center at Houston USA (Hulin.Wu@uth.tmc.edu)
Henry F. Chambers, Division of Infectious Diseases, University of California San Francisco, USA (Henry.Chambers@ucsf.edu)
Anthony Harris, University of Maryland School of Medicine, USA (firstname.lastname@example.org)
Norberto Pantoja-Galicia, Office of Biostatistics, Center for Devices and Radiological Health, U.S. Food and Drug Administration, USA (Norberto.Pantoja-Galicia@fda.hhs.gov)
Gene Pennello, Office of Biostatistics, Center for Devices and Radiological Health, U.S. Food and Drug Administration, USA (Gene.Pennello@fda.hhs.gov)